Overall, nine studies (1948 patients) were included in the analysis of DFS for the comparison between the EGFR-TKI group (TKI only/TKI plus chemotherapy) and the non-EGFR-TKI (control) group (placebo/chemotherapy) in an adjuvant setting for patients with resected EGFR-mutant NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.